Advertisement
Canada markets closed

  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • Bitcoin CAD

    88,527.62
    +1,049.45 (+1.20%)
     

  • CMC Crypto 200

    1,334.09
    +21.46 (+1.64%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     

  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Stocks in play: Medexus Pharmaceuticals Inc.

Baystreet.ca

Announced that the Toronto Stock Exchange has accepted Medexus’s notice of intention to make a normal course issuer bid (NCIB). Under the NCIB, Medexus may purchase for cancellation up to $3,530,000 principal amount of its 6% unsecured convertible debentures due 2023, representing approximately 10% of the public float (defined under TSX rules) and approximately 8.5% of the $41,546,000.00 principal amount of Debentures outstanding as of January 31. Medexus Pharmaceuticals Inc. shares T.MDP are trading down $0.02 at $3.31.

Read: